XTL Biopharma faces shareholder bid for derivative suit seeking NIS 100 million damages

• XTL Biopharmaceuticals was served on Aug. 3, 2026 with a shareholder motion in Tel Aviv-Jaffa court seeking permission to bring a derivative suit.
• Claims target the controlling shareholder plus current and former directors and officers over the 2024 acquisition of The Social Proxy.
• Allegations include duty breaches tied to funding commitments, conflicts of interest, delayed disclosure on loss of control, financial irregularities; unit entered liquidation Feb. 22, 2026.
• Motion seeks damages for alleged loss of subsidiary value, estimated at about NIS 100 million for court-fee purposes, plus disgorgement.
• Additional requests include appointing a forensic accountant to review the company’s and subsidiary’s books; the motion is being contested.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XTL Biopharmaceuticals Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-085693), on August 05, 2026, and is solely responsible for the information contained therein.